Lancet
-
The enduring tensions between medicine and the media are largely due to the different perspectives of biomedical scientists and journalists, as this final essay in the series on medicine and the media underscores. These tensions arise because of perceived differences in defining science news, conflicts over styles of science reporting, and most of all disagreement about the role of the media. In the 1990s, scientists are especially concerned by media messages that question their credibility. Since scientists and journalists depend on each other in the communication of science and the shaping of the public meaning of science and medicine, the tensions are likely to increase.
-
Letter Case Reports
Nitrous oxide and morphine in children with sickle cell crisis.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European Carotid Surgery Trial.
The objective of this study was to assess whether carotid endarterectomy is an appropriate treatment for patients with recent cerebrovascular events in the territory supplied by a moderately stenosed (30-69%) internal carotid artery. Results have previously been reported for severe (70-99%) and mild (0-29%) stenosis. ⋯ Previous interim results from this study showed that surgery is beneficial in patients with severe stenosis but harmful in those with mild stenosis. With more randomised patients and longer follow-up, the study now shows that endarterectomy is not indicated for most, possibly all, patients with moderate symptomatic carotid stenosis.
-
Clinical Trial
A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.
Human papillomavirus (HPV) infection, especially with type 16 or 18, is associated with cervical cancer. Two HPV proteins, E6 and E7, are consistently expressed in tumour cells. The objectives of the study were to examine the clinical and environmental safety and immunogenicity in the first clinical trial of a live recombinant vaccinia virus expressing the E6 and E7 proteins of HPV 16 and 18 (TA-HPV). ⋯ Further studies to investigate the use ot TA-HPV for immunotherapy of cervical cancer are warranted.